GLP-1 and SGLT2 inhibitors show promise in preventing recurrent stroke and heart attack

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death in adults who had an initial stroke, according to a preliminary study to be presented at the American Heart Association’s Scientific Sessions 2024.

Digital health company DarioHealth buys mental health startup Twill as consolidation hits the industry

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Chronic health conditions management platform DarioHealth is

February 22, 2024

Eisai projects near-term Leqembi sales ‘considerably higher’ than analyst forecasts

Eisai is hoping to grow Leqembi sales 13-fold to around $360 million in fiscal year 2024, as it plans “aggressive investment” and looks to expand

May 16, 2024

COVID Drug and New Mutations; Costco Offers $29 Care; Trump Unmasked Over Bronzer

Note that some links may require registration or subscription. The COVID-19 antiviral molnupiravir (Lagevrio) was linked with new mutations of the virus. (Nature) Spending opioid

September 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.